Koji Izutsu

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Somatic RHOA mutation in angioimmunoblastic T cell lymphoma

Mamiko Sakata‐Yanagimoto, Terukazu Enami, Kenichi Yoshida et al. · Nature Genetics · 2014 · 642 citations

Medicine, Cancer Biology, Oncology +14

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda et al. · Nature · 2016 · 638 citations

Medicine, Molecular Genetics, Oncology +16

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 602 citations

Pharmacy, Oncology, Pharmacotherapy +13

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9